Capturing the Cellular Gymnastics of Survival and Killer Proteins by Mass Cytometry (CyTOF)
Walter and Eliza Hall Institute
1g Royal Parade
See more events from
The mass cytometry (CyTOF) technology is a breakthrough new technology that can provide new insights into complex biological systems. It allows high-throughput detection of up to 100 characteristics on a single cell simultaneously. This is more than five times the amount of data generated by existing technology. We coupled this technology with a unique suite of 26 probes to profile cell survival/cell death, cell-cycle status and cellular signalling to understanding changes in blood cancer cells before and after treatment with five different therapeutic agents (bortezomib, lenalidomide, dexamethasone, JQ-1 and iBclxL). We used high-dimensional progression analysis with the FLOW-Map alogorithm to compare the changes in single cells over time following treatment with the five common blood cancer therapeutics. While there were some shared reprogramming landmarks across all treatments, there were also some changes that were unique to particular treatments. We provide a comprehensive reference for dynamic changes occurring during drug treatment. The results shed light on the specific action of the cancer drug on life/death of cancerous blood cells, and may reveal why certain patients are sensitive or resistant to particular therapies.
No registration is required